José M. Padrón, a native of Puerto de la Cruz in the Canary Islands, is a distinguished scientist and Full Professor of Organic Chemistry at the Universidad de La Laguna (ULL). He graduated with honors in Pharmacy from ULL in 1991, beginning his research career with a PhD thesis on the asymmetric synthesis of biologically active molecules under the supervision of Prof. Víctor S. Martín at ULL's Instituto Universitario de Bio-Orgánica (IUBO), and obtaining his doctorate in 1996.
Padrón coauthors over 200 scientific articles and has been principal investigator of a number of research projects. In recognition of his scientific impact, Padrón is among 31 researchers from ULL included in Stanford University's ranking of the world's top 2% most influential scientists. Additionally, he has held key roles within ULL, serving as Director of the Office of Technology Transfer (OTRI) from 2013 to 2015 and as Secretary of IUBO from 2019 to 2023. Padrón currently serves as Director of IUBO, where he continues to lead pioneering research in molecular pharmacology.
José M. Padrón, a native of Puerto de la Cruz in the Canary Islands, is a distinguished scientist and Full Professor of Organic Chemistry at the Universidad de La Laguna (ULL). He graduated with honors in Pharmacy from ULL in 1991, beginning his research career with a PhD thesis on the asymmetric synthesis of biologically active molecules under the supervision of Prof. Víctor S. Martín at ULL's Instituto Universitario de Bio-Orgánica (IUBO), and obtaining his doctorate in 1996.
Padrón coauthors over 200 scientific articles and has been principal investigator of a number of research projects. In recognition of his scientific impact, Padrón is among 31 researchers from ULL included in Stanford University's ranking of the world's top 2% most influential scientists. Additionally, he has held key roles within ULL, serving as Director of the Office of Technology Transfer (OTRI) from 2013 to 2015 and as Secretary of IUBO from 2019 to 2023. Padrón currently serves as Director of IUBO, where he continues to lead pioneering research in molecular pharmacology.